Base de dados : HANSEN Pesquisa : HANSENOSTATICOS/EF ADV [Descritor de assunto] Referências encontradas : 32 [refinar] Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 2

ir para página

1 / 32

HANSEN

seleciona para imprimir

Id: 24736 Autor: Desforges, J. F; Thayer, W. W; Dawson, J. P Título: Hemolytic anemia induced by sulfoxone therapy, with investigations into the mechanisms of its production ?- Fonte: Boston; s.n; 1960. 5p p. ilus. Resumo: A case report is presented of a patient in whom clinical evidence of hemolytic anemia with methemoglobinemia developed upon increasing the dosage of sulfoxone which he was receiving for Hansen's disease. Administration of the drug was withdrawn for six weeks, after which studies were made with the use of radioactive iron to demosntrate the hemolytic effect of sulfoxone. By means of tagging cells of a single age group, it was shown that the suceptibility to hemolysis was related to cell age, and it was only after the red cells had been in the circulation for approximately fifty days that they were subject to the hemolytic effects of this drug. No significant biochemical defect could be demonstrated in the erythrocytes of this patient. However, the decline in activity of glucose-6-phosphate dehydrogenase and glutathione reductase in the aging red cell and the reported sensitivity to this drug of patients with red cell deficiency of glucose-6-phosphate dehydrogenase suggest that the hemolytic mechanism is related to this enzyme system. The case demonstrates that drug-induced hemolytic anemia of this type may occur without demonstrable enzymatic defect of the erythrocytes. The observation that patients appear to compensate for the hemolytic anemia and methemoglobinemia if maintained on this drug may be explained by the fact that the older cells containing less adequate enzyme systems are removed from the circulation and an equilibrium is maintained by increased production of red cells with a shorter age span. Descritores: HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/sangue HANSENOSTATICOS/uso terap ANEMIA HEMOLITICA/ind quim ANEMIA HEMOLITICA/diag ANEMIA HEMOLITICA/etiol - HANSENIASE/clas  HANSENIASE/compl  HANSENIASE/diag  HANSENIASE/terap Limites: RELATO DE CASO Localização: BR191.1; 00720/s

2 / 32

HANSEN

seleciona para imprimir

Id: 23010 Autor: Trautman, J. R Título: The management of leprosy and its complications ?- Fonte: Louisiana; s.n; 1965. 10p p. . Descritores: HANSENIASE/compl HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap ERITEMA NODOSO/quimioter NEURITE/quimioter NEURITE/fisiopatol AMILOIDOSE/dietoter Limites: RELATO DE CASO Localização: BR191.1; 01106/d.a

3 / 32

HANSEN

seleciona para imprimir

Id: 22351 Autor: S, B. B. M. Dharmendra; Chatterjee, K. R. Título: Thiosemicarbazone in the treatment of leprosy. Fonte: Lepr Ind;24(3):93-, july, 1952. tab. Resumo: (I) The previous work with thiosemicarbazone in the treatment of leprosy is summarised. (2) Siocarbazone brand of thiosemicarbazone has been used in 52 cases of leprosy, 9 untraeded neural cases, 27 untreated lepromatous cases and 16 previously treated lepromatous cases, 15 with sulphones, and I with hydnocarpus oil. The duration of treatment has from 2 months to 16 months with an average of I0 months. (3) The patients have stood the drug well and there has been satisfactory clinical and bacteriological response. In addition to usual therapeutic affects, special features with thiosemicarbazone treatment have been the complete or partial restoration of sensation in the anaesthetic patches and in the limbs with polyneuritic type of anaesthesia, replacement of deseased nails by new ones, and growth of new hair in depilated areas. Considering the short period of treatment those features are rather remarkable. (4) In the toxicity of thiosemicarbazone seems to be less than that of the sulphones specially in relation to its effect on the haemopoietic system. However, the thiosemicarbazone is not as free from toxicity as described by some workers eho have used it in leprosy. A special kind of toxicity which indicates specific intolerance has been noticed and this has been manifested by sudden rise of temperature even after small doses of the drug (AU). Descritores: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/farmacol HANSENOSTATICOS/tox HANSENOSTATICOS/uso terap Localização: BR191.1

4 / 32

HANSEN

seleciona para imprimir

Id: 21493 Autor: Paget, H; Trevan, J. W; Attwood, A. M. P. Título: The irritant action of some drugs derived from hydnocarpus oil. Fonte: Int. J. Lepr;7(2):167-173, Apr.-Jun. 1939. tab. Resumo: 1- An acid value of 3 is sufficient to render hydnocarpus preparations irritant. 2- Hemolysis is caused rapidly by salts of hydnocarpus acids in normal saline but it is so far inhibited by the presence of serum that it cannot be considered an important factor in causing pain on injection. 3- The amount of formic acid present in ethyl esters which have deteriorated is insufficient to account for more than a small part of the irritation. 4- Aralkyl esters (thymyl-, phenylethyl-, cinnamyl-, and menthyl-) of the crystalline acids are less irritant than the ethyl esters, causing no necrosis on intradermal injection. 5- Iodized ethyl esters of the crystalline acids are unstable on exposure to air, but oxidation is inhibited by addition of 0.1 percent of catechol or pyrogallol. (AU). Descritores: HANSENIASE HANSENIASE/quimioter HANSENOSTATICOS/ef adv Meio Eletrônico: - . Localização: BR191.1

5 / 32

HANSEN

seleciona para imprimir

Id: 20937 Autor: Roy, A. T. Título: Ulcers caused by the intradermal injection of ethyl esters of hydnocarpus oil. Fonte: Lepr Ind;7(3):124-126, july, 1935. . Descritores: HANSENIASE/quimioter HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap Localização: Br191.1

6 / 32

HANSEN

seleciona para imprimir

Id: 20888 Autor: Lowe, J. Título: A note on the action of chaulmoogra (Hydnocarpus) preparations on M. Leprae Muris. Fonte: Lepr Ind;6(2):79-, apr., 1934. . Descritores: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv Limites: ANIMAL Localização: BR191.1

7 / 32

HANSEN

seleciona para imprimir

Id: 20880 Autor: Muir, E. Título: Some factors influencing the nature of leprous lesions. Fonte: Lepr Ind;6(1):12-18, Jan., 1934. . Descritores: HANSENIASE/clas HANSENIASE/diag HANSENIASE/quimioter HANSENOSTATICOS/ef adv Localização: BR191.1

8 / 32

HANSEN

seleciona para imprimir

Id: 20814 Autor: Lowe, John. Título: Hydnocarpus oil and its ethyl esters. Fonte: Lepr Ind;4(4):188-195, oct. 1932. ilus. Descritores: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/sint quim HANSENOSTATICOS/isol HANSENOSTATICOS/provis HANSENOSTATICOS/uso terap Limites: HUMANO Localização: BR191.1

9 / 32

HANSEN

seleciona para imprimir

Id: 20777 Autor: Percy, M Peacock C. Título: Ascomycetes in the treatment of leprosy. Fonte: Lepr Ind;4(1):11-12, jan. 1932. . Descritores: HANSENIASE/quimioter HANSENIASE/hist HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/hist HANSENIASE/compl Localização: BR191.1

10 / 32

HANSEN

seleciona para imprimir

Id: 20765 Autor: Kaluarachchi, S. I; Fernandopulle, B. M. R; Gunawardane, B. P Título: Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy - a five year retrospective study ..- Fonte: s.l; s.n; 2001. 9 p. tab. Resumo: This study analyses retrospectively some of the risks associated with the use of WHO-multidrug therapy (MDT) in Sri Lanka. Case records of 3,333 new cases of leprosy attending the Central Leprosy Clinic in Colombo during 1991-1995, were analysed for adverse drug reactions involving the liver and blood. There were 81 reports of suspected hepatic or haematological adverse reactions associated with the use of MDT, of which 39 were classified as haemolytic anaemia, 25 as toxic hepatitis, 2 as methaemoglobinaemia and 15 as anaemia. Dapsone, was incriminated in the majority of adverse reactions (72 per cent). Adverse drug reactions were more common in female than male subjects (55 per cent vs 45 per cent; P < 0.5), but there was no significant differences between the age groups. Majority of adverse reactions was seen within the first three months of initiation of MDT. This study in no way undermines the benefits of MDT but highlights the risks and suggests measures to minimize these risks. (AU). Descritores: ANEMIA/ind quim ANEMIA/epidemiol CLOFAZIMINA/ef adv DAPSONA/ef adv QUIMIOTERAPIA COMBINADA HEPATITE TOXICA/epidemiol HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/quimioter ESTUDOS RETROSPECTIVOS RIFAMPINA/ef adv RIFAMPINA/uso terap METEMOGLOBINEMIA/ind quim METEMOGLOBINEMIA/epidemiol Limites: HUMANO MASCULINO FEMININO CRIANÇA ADULTO MEIA-IDADE ADOLESCENTE Meio Eletrônico: - . Localização: BR191.1; 09163/s

11 / 32

HANSEN

seleciona para imprimir

Id: 20764 Autor: Ishii, Norihisa Título: Recent advances in the treatment of leprosy ..- Fonte: s.l; s.n; 2003. 9 p. tab. Resumo: Leprosy, a chronic infectious disease caused by Mycobacterium leprae, was identified by G. H. A. Hansen in 1873. The different clinical presentations of the disease are determined by the quality of the host immune response. The bacteria have affinity for the peripheral nerves and are likely the cause of neuropathy, a cardinal manifestation of the disease. WHO recommends a protocol of multidrug therapy (MDT), which effectively controls the disease, hence contributing to the global elimination program. Early detection of leprosy and treatment by MDT are the most important steps in preventing deformity and disability. (AU). Descritores: COMORBILIDADE PAISES EM DESENVOLVIMENTO ESQUEMA DE MEDICACAO Resistência Bacteriana a Drogas QUIMIOTERAPIA COMBINADA HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENIASE/clas HANSENIASE/diag HANSENIASE/quimioter HANSENIASE/epidemiol PREVALÊNCIA Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1; 09160/s; BR191.1; 09161/s

12 / 32

HANSEN

seleciona para imprimir

Id: 20709 Autor: Muir, E. Título: The irritative qualities of hydnocarpus oil and its prepartations. Fonte: Lepr Ind;2(4):126-137, oct.1930. ilus, tab. Descritores: HANSENIASE/compl HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/hist HANSENOSTATICOS/uso terap HANSENIASE/diag HANSENIASE/econ HANSENIASE/epidemiol Localização: BR191.1

13 / 32

HANSEN

seleciona para imprimir

Id: 20686 Autor: Kerr, I. Título: Treatment of leprosy with theyroid extract. Fonte: Lepr Ind;2(2):39-40, apr. 1930. . Descritores: HANSENIASE/quimioter HANSENIASE/hist HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap Limites: HUMANO Localização: BR191.1

14 / 32

HANSEN

seleciona para imprimir

Id: 20676 Autor: Anon. Título: Gereral Notes. Fonte: Lepr Ind;1(2):31-34, Oct. 1929. . Descritores: HANSENIASE/quimioter HANSENIASE/hist HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/isol HANSENOSTATICOS/uso terap Localização: BR191.1

15 / 32

HANSEN

seleciona para imprimir

Id: 20498 Autor: Ota, Masao; Sato, Saburo; Masuzawa, Tatsuro. Título: A chaulmoogra preparation for intravenous use, and its therapeutic effect. Fonte: Int. J. Lepr;3(2):153-164, Apr.-Jun. 1935. tab. Descritores: CHAULMOOGRA/admin CHAULMOOGRA/ef adv CHAULMOOGRA/uso terap - HANSENIASE/quimioter  HANSENOSTATICOS/admin  HANSENOSTATICOS/ef adv  HANSENOSTATICOS/isol  HANSENOSTATICOS/uso terap Localização: BR191.1

16 / 32

HANSEN

seleciona para imprimir

Id: 20478 Autor: Baez, Pedro Ramos. Título: Allergic eruthematous eruptions in leprosy. Fonte: Int. J. Lepr;3(1):23-32, Jan.-Mar. 1935. ilus, tab. Descritores: HANSENIASE HANSENIASE/clas HANSENIASE/compl HANSENIASE/diag HANSENIASE/patol - HANSENOSTATICOS/ef adv  HANSENOSTATICOS/uso terap Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1

17 / 32

HANSEN

seleciona para imprimir

Id: 20446 Autor: Wade, H. W. Título: Tuberculoid changes in leprosy. III. The pathology of a nerve abscess. Fonte: Int. J. Lepr;2(3):293-300, Aug.-Oct. 1934. ilus. Resumo: A description is given of the histopathology of a specimen of the peculiar chronic leprous nerve abscess of India, the frequency of wich in that country - if not its occurrence at all - constitutes one of the regional peculiarities of the disease. The tissue is a highly organized tuberculoid granuloma, with outer capsular and inner pseudo-villous layers. The latter consists of isolated, vascular lymphoid follicles clothed top and sides with a layer of proliferating tuberculoid tissue; necrosis of this occuring beyond a given distance produces villosities in a strikingly regular manner. The cpsule is of comparatively finely-knit structure, well supplied with vessels; it apparently derived from the perineurium, indicating that the process arose within a nerve cord. This finding, in view of the evident frequence of tuberculoid affection of the nerve in India, and on the other hand the non occurrence in the Philippines of abscess of this kind and the rarity and unimportance there of tuberculoid lesions of the nerve, indicates that the latter forms the basis of the former. In view of the clinical features, and especially of Lowe´s opinion that this absces formation is a reaction condition and greatly increased in frequency by the use of potassium iodite, it is accepted as entirely probable that the condition is a manifestation of lepra reaction and, more specifically, of chronic, persistent lepra reaction in a tuberculoid lesion. The extensive epithelioid production is in keeping with findings in chronic reaction of tuberculoid skin lesions and is a further indication that that feature is characteristic of chronic reaction in lesions of that nature. Leprosy bacilli were not found in this specimen, though Lowe found a few, apparently degenerated, in about half of his cases. However, though there is need of further control work, the causative agent is in all probability that of leprosy. It is believed that these abscesses are worthy of further attention. It remains to be determined whether they are regularly tuberculoid and regularly associated with reaction. The fact that they are apparently limited to males involves an intriguing question. Finally, material from these lesions might prove of special value in an investigation of the hypothetical submicroscopic form or phase of the leprosy bacillus. (AU). Descritores: HANSENIASE TUBERCULOIDE/diag HANSENOSTATICOS/ef adv HANSENOSTATICOS/farmacol HANSENOSTATICOS/uso terap - GRANULOMA/patol Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1

18 / 32

HANSEN

seleciona para imprimir

Id: 20445 Autor: Wade, H. W. Título: Tuberculoid changes in leprosy: II. Lepra reaction in tuberculoid leprosy. Fonte: Int. J. Lepr;2(3):279-292, Aug.-Oct. 1934. ilus. Resumo: 1- Six cases are described of probable lepra reaction seen among the forty cases of evident tuberculoid leprosy examined at Emjanyana, in South Africa. Four were diagnosed by the clinician as in the reaction condition, two of mild grades and two severe and protracted; the last two were both found bacteriologically positive and were biopsied. The other two cases (both bacteriologically positive, one biopsied) were probably also in reaction but were not so diagnosed. Certain preliminary observations of the condition are noted. 2- As with lepra reaction in ordinary leprosy, the existing cause is usually not determinable, though potassium iodide is apt to precipitate it. Duration seems prone to be long, with no evident relation to the degree of the reaction phenomenon. In the more severe degrees the general disturbance appears less severe than in similarly extensive reactions in the cutaneous type of leprosy. As a whole the clinical features rermain to be established. 3- The four definite cases all show apparent activity of the borders of the lesions, with increased erythema, infiltration, and even scaling and erosion in the more severe ones. Whether limited, localized reactions accur as in ordinary leprosy, and if so whether they can be positively recognized, is uncertain but seems probable. 4- Histologically the lesions examined show only tuberculoid changes, the more marked ones with epithelioid production of an extreme degree believed to be characteristic of prolonged severe reaction. It is considered probable that lesions with mild degrees of reaction. It is demonstrated that the presence of relatively numerous bacilli does not necessarilly involve departure from the tuberculoid condition...(AU). Descritores: HANSENIASE TUBERCULOIDE/compl HANSENIASE TUBERCULOIDE/diag HANSENIASE TUBERCULOIDE/quimioter HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap Limites: HUMANO Meio Eletrônico: - . Localização: BR191.1

19 / 32

HANSEN

seleciona para imprimir

Id: 20441 Autor: Emmerson, George A; Anderson, Hamiilton H. Título: Toxicity of certain proposed antileprosy dyes: fluorescein, eosin, erythrosin, and others. Fonte: Int. J. Lepr;2(3):257-263, Aug.-Oct. 1934. tab. Resumo: Fluorescein, eosin, erythrosin and methylene green were found to be lethal at 300, 350, 200 and 150 mgm. per kilogram, respectively when administered intravenously to rabbits, and at 600, 500, 300 and 125 mgm. per kilogram intraperitoneally in rats. Methylene green is lethal for anesthetized cats in doses of 50 to 75 mgm. per kilogram. Orally in rats these dyes are tolerated in doses of 1.0 gm. per kilogram with the exception of methylene green, which killed 2 of 5 rats at 500 mgm. per kilogram. Data are presented on the chronic toxicity of trypan blue, gentian violet, brillant green and mercurochrome. Three of 6 rabbits dying under repeated intravenous administrations of trypan blue had received a total cumulative dose, approximately equivalent to but one acute lethal dose, i.e., 120 to 150 mgm. per kilogram. The dangers of repeatedly using high doses in human lepers, the superiority of oral administration over intravenous, and the danger of certain synergizing agents, including photodynamic effects, are discussed. (AU). Descritores: HANSENIASE/quimioter HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/tox Limites: ANIMAL Localização: BR191.1

20 / 32

HANSEN

seleciona para imprimir

Id: 20420 Autor: Trevan, J. W; Attwood, A. M. P. Título: The irritant constituent of anti-leprotic oils. Fonte: Int. J. Lepr;2(2):149-158, Apr.-July 1934. tab. Resumo: The constituent fractions of the acids of sapucainha oil have been separated by cold processes as afr as possible and tested for irritant properties. A crystalline acid fraction (chaulmoogric, hydnocarpic and palmitic acids), an oily acid (5 per cent), and a keto-acid (4,5 per cent), gave bland ethyl esters and sodium salts. The only product to exhibit marked irritant properties was a tarry acid fraction (9 per cent), which appeared to consist essentially of a lactonic acid. The ethyl esters of the crystalline acids were not rendered irritant by distillation at 350°/760 mm., but on long exposure in thin layers to ligh and air they change in physical and chemical character and become highly irritant, possibly owing to the production of the lactonic acid above mentioned. (AU). Descritores: HANSENOSTATICOS/admin HANSENOSTATICOS/ef adv HANSENOSTATICOS/uso terap HANSENOSTATICOS/anal - CHAULMOOGRA/anal  CHAULMOOGRA/isol Localização: BR191.1

---

página 1 de 2

ir para página

Refinar a pesquisa

Base de dados : HANSEN

Formulário avançado

Pesquisar por : Formulário livre

		Pesquisar	no campo
1			PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
2	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
3	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro

Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information